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ABSTRACT 
 
 
Hsin-I (Cindy) Hung 
Combined gene therapy of siRNA and apoptosis inducing factor 
generated from a single transcriptional event  
  
(Under the direction of Leaf Huang, Ph.D.) 
 
The goal of this project is to test the hypothesis that a single transcriptional event driven by 
RNA polymerase II promoter driven siRNA expression plasmid that utilized RNA splicing 
mechanism. During this event, a specific siRNA to a target oncogene, forms from the 
spliced intron; meanwhile a therapeutic protein is established after rejoining of the exon 
fragments. In this case, the well-known, strong RNA polymerase II (CMV) promoter was 
used to produce an siRNA against several well known oncogenes and a therapeutic protein, 
Apoptosis Inducing Factor (AIF), as a dual therapeutic to induce tumor cells apoptosis 
simultaneously from a single plasmid construct. By using this splicing approach with 2 
different targeting mechanisms (i.e., oncogene inhibition by siRNA and therapeutic protein 
expression), we expect to see a synergistic effect from our novel RNA polymerase II 
promoter-driven plasmid.  It was demonstrated that the plasmid construct achieved up to 40 
percent siRNA inhibition, as well as increased apoptosis of cells transfected after cloning of 
the therapeutic exon component. In addition, by using a DNA-vector driven siRNA 
expression system, we can reduce the cost of producing siRNA and increase the duration of 
siRNA efficacy to achieve long term effects of gene silencing. Thus, by utilizing the 
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combination of these 2 different targeting mechanisms from the RNA splicing process, we 
expected that the strategy will bring us a new affordable and promising way for efficient 
cancer cell targeting and treatment.  Combined with the consistent and satisfactory lipid-
based delivery system previously described by our lab (Li & Huang, 1997; Li et al, 2008; Li 
& Huang, 2006), we anticipate a greatly improved cancer targeting therapy.  
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ABBREVIATIONS 
 
 
 
AIF: Apoptosis inducing factor 
 
B16F10: Murine melanoma cells with GL3 transduced 
 
EGFP: Enhanced green fluorescent protein 
 
EGFR: epidermal growth factor receptor 
 
EM22: pEGFP-N1 plasmid removed PstI site from MCS and added PstI site                
within EGFP by silent mutagenesis, (pEGFP-PstI+PstI) 
 
EMC: pEGFP-PstI+PstI+artificial Intron+control scramble siRNA 
 
EM-E6: pEGFP-PstI+PstI+artificial Intron+HPV E6 siRNA 
 
EM-EGFR: pEGFP-PstI+PstI+artificial Intron+EGFR siRNA 
 
EM-intron:                    pEGFP-PstI+PstI+artificial Intron 
 
EML6: 6th clone of pEGFP-PstI+PstI+artificial Intron+Luciferase siRNA 
 
EML8: 8th clone of pEGFP-PstI+PstI+artificial Intron+Luciferase siRNA 
 
EM-VEGF: pEGFP-PstI+PstI+artificial Intron+VEGF siRNA 
 
HHI-80:                        AIF inserted ahead of EGFP gene in the pEGFP-N1 (MCS 15 clone) 
 
HPV: Human papillomavirus 
 
SPL:                              EGFP replaced by AIF in the pEGFP-N1 (Rep 23 clone) 
 
STS: Staurosporine  
 
VEGF: Vascular endothelial growth factor
 
 
 
 
Introduction 
 
 
RNA interference (RNAi) is a powerful cellular mechanism to destroy target specific 
mRNAs. In 1995, Guo and Kemphues (Guo & Kemphues, 1995) first found that either 
strand of  sense or antisense RNA alone is efficient to suppress gene expression in worms. 
Subsequently, Fire et al. (Fire et al, 1998) further found that double-stranded RNAs 
(dsRNAs) were more effective at producing interference than either strand individually. 
Fire and coworkers (Fire et al, 1998) then coined the term “RNA interference (RNAi)” to 
describe the  inhibition of gene expression by dsRNAs.  RNAi was first discovered in 
plants and lower eukaryotic organisms but was later observed as an important genetic 
regulatory mechanism in mammalian cells (van Rij & Andino, 2006). The mechanism of 
RNAi involves a multistep process to generate the small interfering RNAs (siRNAs), 
which act as triggers for targeted RNA degradation (Dykxhoorn et al, 2006).  In brief, first, 
an RNAse III type enzyme, Dicer, will cleave double stranded RNAs into short 21-23 base 
pair duplexes. Then, the antisense strand of RNA is incorporated into a protein complex, 
RISC (RNA induced silencing complex), which has helicase, endonuclease activity.  The 
antisense strand RNA will then guide the whole protein complex to its target 
complementary sequence, followed by endonucleolytic cleavage of the target mRNA and 
recycling of RISC.(Dykxhoorn et al, 2006; Steinman et al, 2004; Tiscornia et al, 2003; 
Wang et al, 2008).  One particular benefit of RNAi is that siRNAs have not been found to 
activate interferon pathway genes in mammalian cells, largely owning to their short length, 
thereby making this a powerful tool for sequence specific knockdown of RNAs. 
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siRNAs are typically generated either by chemical synthesis or DNA-vector-mediated 
methods. While chemically synthesized siRNAs are frequently used and have shown some 
advantages such as high transient inhibition efficiency and easy to conduct, they also have 
some major drawbacks: cost and short half-life (Fewell & Schmitt, 2006). Chemically 
synthesized siRNAs generally last 2-5 days in in vitro systems and provide only transient 
knockdown activity, which together with their high cost make this approach unsuitable for 
the analysis of the long-term effects of gene silencing. While DNA-vector-mediated 
methods are time-consuming, laborious and with extra nuclear barrier concern (Dykxhoorn 
et al, 2006; Wang et al, 2008), it is looked to as an alternate, affordable means to achieve 
long-term effects of gene silencing. 
Non-viral DNA-vector-mediated siRNA can be driven either by RNA polymerase II 
or RNA polymerase III promoters.  RNA polymerase III promoter such as U6, H1, and 
tRNA have been widely used in non-viral DNA-vector-mediated siRNA studies because of 
their high driving efficiency (Kawasaki & Taira, 2003; Tiscornia et al, 2003; Xia et al, 
2004).  In addition, the constructs containing RNA polymerase III promoter are small, 
simple and easily inserted into viral vectors.   However, those RNA polymerase III 
constructs tend to have minimal cell specificity, and their high driving activity increases the 
possibility of off-target and non-specific silencing effects, which in turn could trigger an 
interferon response and cellular toxicity (Bridge et al, 2003; Jackson et al, 2003). In 
contrast, many RNA polymerase II promoters, such as the CMV promoter, are known to be 
successfully in direct cell or tissue-specific gene silencing and transgenic animal studies 
(Lin SL, 2003). Furthermore, RNA polymerase II promoter directed synthesis of short 
hairpin RNA (shRNA) mimic the well-known natural miRNA synthesis and therefore, 
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could be an efficient strategy to study RNAi silencing (Greber & Fussenegger, 2007; Lin 
SL, 2003; Wang et al, 2008). In order to overcome the limitations of the currently 
commonly used RNA polymerase III promoter driven siRNA expression system, we made 
an effort to study the RNA polymerase II promoter driven siRNA expression system. Here, 
by taking advantage of the splicing mechanism from an RNA polymerase II promoter 
driven shRNA-forming plasmid, we expect to achieve a synergistic cancer treatment by 
using 2 complimentary mechanisms that include an oncogene targeted siRNA from the 
intron and a therapeutic protein from the exons. Together with the well-established delivery 
methods from our lab, we hope to achieve a better targeted cancer treatment.
  
 
Materials and Methods 
Cell lines and drug treatments 
B16F10 cells, murine melanoma cells, were obtained from the American Type Cell 
Collection (Manassas, VA) and were stably transduced with GL3 firefly luciferase gene 
using a retroviral vector from Dr. Pilar Blancafort’s lab at the University of North Carolina 
at Chapel Hill.  TC1 cells were obtained from ATCC. Both cells were grown in Dulbecco's 
modified Eagle's medium containing 10% heat-inactivated fetal bovine serum, 100 units/ml 
penicillin, and 100 μg/ml streptomycin.  
Plasmids 
A commercial available EGFP containing plasmid, pEGFP-N1was purchased from 
(Clontech, Mountain View, CA) as parental plasmid for all the subsequent modification. 
Silent mutagenesis was carried out by using site-directed mutagenesis kit (Stratagene, La 
Jolla, CA) according to the manufacturer's instructions with a pair of complementary 
primers to create Pst I site on the pEGFP-N1. Silent mutagenesis primers were: 5' - CCT 
GCT GGA GTT CGT GAC CGC TGC AGG GAT CAC TCT CGG CAT GGA C - 3' and 
5' - GTC CAT GCC GAG AGT GAT CCC TGC AGC GGT CAC GAA CTC CAG CAG G 
- 3' Artificial intron fragment was synthesized by company (Integrated DNA Technology, 
Inc.). Sequence of anti-HPV E6 siRNA, anti-EGFR siRNA, anti-VEGF siRNA, control 
scramble siRNA, and anti-Luciferase siRNA were adapted from the literature (Shih et al, 
2002; Song et al, 2005; Steinman et al, 2004; Zhang et al, 2005)  and synthesized 
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(Integrated DNA Technology, Inc., Coralville, IA) as templates for the PCR reaction.  PCR 
was performed using the following PCR primers (Integrated DNA Technology, Inc.) and an 
ABI PRISM 7900HT PCR machine (Applied Biosystems, Foster City, CA): for anti-HPV 
E6 siRNA , 5' - AAT TAA TGA TCA CGA TCG ACG CGT GGA TCC CGC TTG CAG T 
- 3'  and 5' - TTC CTT ACT AGT AGT ACT TCG CGA GGT ACC TTG GAA AAA AGC 
TTG CAG TAC ACA CAT TCC - 3' ; anti-EGFR siRNA, 5' - AAT TAA TGA TCA CGA 
TCG ACG CGT GGA TCC CAG GAA TTC G - 3' and 5' - TTC CTT ACT AGT AGT 
ACT TCG CGA AAG CTT TTG GAA AAA AAG GAA TTC GCT CC - 3'; anti-VEGF 
siRNA, 5' - AAT TAA TGA TCA CGA TCG ACG CGT GGA TCC CGC ACT CCA G - 3' 
and 5' - TTC CTT ACT AGT AGT ACT TCG CGA AAG CTT TTG GAA AAA AGC 
ACT CCA GGG CTT CAT - 3'; control scramble siRNA, 5' - AAT TAA TGA TCA CGA 
TCG ACG CGT GGA TCC CAC GTG ACA C - 3' and 5' - TTC CTT ACT AGT AGT 
ACT TCG CGA AAG CTT TTG GAA AAA AAC GTG ACA CGT TCG G - 3'; anti-
Luciferase siRNA, 5' - AAT TAA TGA TCA CGA TCG ACG CGT GGA TCC CGT CGA 
AGT ACT C - 3' and 5' - TTC CTT ACT AGT AGT ACT TCG CGA AAG CTT TTG 
GAA AAA ATC GAA GTA CTC AGC GTA AGC - 3'. All the PCR cloned siRNAs 
fragments were subcloned into the intron on modified pEGFP-N1 plasmid with MluI and 
NruI restriction sites. All the cloned fragments and constructs were sequence verified by the 
UNC genome center, sequence facility.  A commercial RNA polymerase III promoter 
driven siRNA expression plasmid was purchased from Genescript as pRNA-siRNA system 
in the study (Genescript). 
RNA Extraction and RT-PCR 
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RNA was extracted by RNeasy kit (QIAGEN). Immediately after extraction, 1 to 2 μg of 
RNA was used for one-step RT-PCR synthesis with SuperScript II (Invitrogen) and 
different primers: AIF primer 5′- AAG GAA CCC GGG TGC GTG GAA GGA AAA GGA 
AGG AGC GGG AGC TTC CG -3′ and 5′- TTC CTT GCG GCC GCC GCC AGG GAT 
GGA AAA GTG CTT GTG TAT TCC ACG A - 3′.  RT-PCR cloned AIF fragment from 
B16F10 cell line was subcloned into pEGFP-N1 plasmid with XhoI and AgeI restriction 
sites. 
Luciferase reporter assay 
 B16F10 cells were seeded in 96-well dishes and transfected using Lipofectamine 2000 
(Invitrogen) with 300 ng of different EM-intron plasmids. After 48 h transfection, cells 
were trypsinized and 2 x 105 cells were collected. Those collected cells were  incubated 
with 100 μl lysis buffer (0.05% Triton X-100 and 2 mM EDTA in 0.1 M Tris-HCl) at room 
temperature for 10 min. Ten microliters of lysate was mixed with 100 μl substrate 
(Luciferase Assay System, Promega Co., Madison, WI) and the luminescence was 
measured by a plate reader. The protein concentrations of the samples were determined by 
using a protein assay kit (Micro BCATM protein assay kit, Pierce, Rockford, IL). Luciferase 
activity of a sample was normalized with the protein content and expressed as percent 
luminescence intensity compared to the positive control, EM-scramble siRNA. 
MTT assay 
 
B16F10 cells grown in 96-well plates with 10% FBS DMEM were incubated to reach at 30-
 
7
40% confluence. The cells were then washed with PBS and 50ul/well of FBS free DMEM 
was added. A 0.3ug quantity of various DNA constructs in 50ul of FBS free DMEM 
containing 1 μl of Lipofectamine 2000 (Invitrogen) was added to the medium in each well. 
After transfection for 48 h, the cells were observed by fluorescent microscope and then 5ul 
MTT substrate was added. An MTT stock solution (5 mg of MTT/ml of distilled water) was 
filter sterilized and kept for no more than 2 weeks at 4°C. To start the coloring reaction, 
stock solution was added to growing cultures (final concentration, 0.5 mg/ml). The mixture 
was incubated for 1 h and the tubes were vortexed. Lysed cells and debris were pelleted 
(15,000 × g, 5 min), and 100 μl of the supernatant was transferred into a 96-well plate. The 
OD was measured with a spectrophotometer (SPECTRAmax PLUS, Molecular Devices) at 
570 nm.  A blank with propanol alone was measured and subtracted from all values. 
 
Statistical analysis 
 
All statistical analyses were performed by the one-way ANOVA or a two-tailed student t-
test. Data were considered statistically significant when P value was less than 0.05.
 
 
 
 
 
 
Results and Discussion 
 
 
Insertion of an artificial intron containing siRNA cloning sites within EGFP by   
silent mutagenesis created PstI site 
 
 
A new strategy for utilizing specially designed plasmid constructs that take advantage 
of RNA splicing mechanism was proposed by Lin and collegues (Lin SL, 2003).  In this 
approach, after splicing, the RNA polymerase II leads to the production of an oncogene 
targeted siRNA from the spliced intron. Furthermore, a functional protein is formed by the 
exons resulting from splicing (Fig.1).  We used pEGFP-N1 plasmid (Clontech) containing 
EGFP as report gene to serve as the parental plasmid to facilitate all subsequently 
subcloning.  In order to apply the aforementioned strategy in our study (Lin SL, 2003), the 
original pEGFp-N1 plasmid was modified allowing the minimum required splicing 
elements to be inserted into the EGFP to create an artificial intron (Fig. 1).  First, the PstI 
site was removed from the multiple cloning site (MCS) of the original pEGFP-N1plasmid 
(pEGFP-N1-PstI) and then a new PstI site was created within EGFP gene by silent 
mutagenesis of the pEGFP-N1-PstI plasmid (pEGFP-N1-PstI+PstI, or EM22) (Fig. 2A)   
Both pEGFP-N1-PstI and EM22 plasmids were sequenced to verify the relocation of the 
site as well as subjected to restriction enzyme digestion by Pst1, to confirm fragment 
formation (Fig. 2B).  After the PstI site was relocated into the EGFP gene to form the 
EM22 plasmid, the minimum splicing required elements containing a donor splicing site, a 
acceptor splicing site, a branch point and a poly-pyrimidine tract as an artificial intron were 
inserted into the EGFP gene ofEM22 (Fig. 3A). The EM22 plasmid containing the artificial 
intron within the EGFP gene is referred to as EM22-intron.   After the EM22-intron was 
sequence verified, its splicing ability was further examined by investigating EGFP levels as 
observed by fluorescent microscopy.  Based on our results (Fig. 3B), it is apparent that both 
EM22 (silent mutagenesis) plasmid and EM22-intron plasmid turned green, indicating the 
splicing mechanism worked in our constructed EM22-intron plasmid.  Moreover, not only 
forward inserted intron plasmids turned green but also those reversed- inserted introns 
turned green, which strongly supports that the splicing mechanism was successfully carried 
out in our EM22-intron plasmids.   
Following the verification of EM22-intron plasmids splicing, siRNA sequences for 
known cancer related genes, such as HPV E6, EGFR, VEGF, and control scramble, were 
inserted into our EM22-intron plasmid. These were verified to be into the forward facing 
intron plasmids (data not shown). The schematic of this step is shown in Fig. 4A and 
resulting PCR product of various siRNAs are shown in Fig. 4B. EM22-intron with HPV E6, 
EGFR, VEGF, and scramble siRNAs insertions, respectively, were sequence verified and 
tested their splicing ability by fluorescent microscopy (Fig.5). We wish to overcome the 
limitations of RNA polymerase III promoter driven siRNA expression system and to 
compare their siRNAs suppressive activity with the RNA polymerase II promoter driven 
siRNA expression system. We have constructed our novel RNA polymerase II promoter 
driven siRNA plasmid which utilizes RNA splicing mechanism as EM-intron –siRNA 
system. A RNA polymerase III promoter driven siRNA expression plasmid was purchased 
from (genescript) as pRNA-siRNA system. Both of these 2 siRNA expression plasmid 
systems (Fig.6) were successfully inserted with HPV E6, EGFR, VEGF and scrambled 
siRNAs individually with sequence verified and fluorescent microscopy examined of the 
EGFP activity.(Fig 4 and Fig 5) (data of RNA polymerase III system not shown).  Our 
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constructs containing RNA polymerase II promoter driven EM22-intron system have shown 
successful intron splicing mechanism as well as produced the functional protein (e.g., 
EGFP). Therefore, we further examined the gene silencing activity from the siRNA spliced 
into the intron region. The B16F10 mouse melanoma cell line, transduced with GL3 firefly 
luciferase gene, was chosen. The luciferase was stably transduced using a retroviral vector 
by Dr. Pilar Blancafort’s lab at the University of North Carolina at Chapel Hill. This 
plasmid was designed to assess the inhibition activity by the anti-Luciferase siRNA.  We 
inserted anti-Luciferase siRNA into an artificial intron of EM22-intron system (Fig. 7A). 
After the sequence was verified, EM22-intron–Luciferase constructs were transfected into 
B16F10 cells and analyzed for their ability to suppress luciferase activity. Based on the data 
shown in Fig. 7B, we found that two specific clones, EML6 and EML8, showed inhibition 
activity.  EML8 was found to down-regulate the luciferase activity about 40% compared to 
EM22-intron (P<0.01, N=45). 
 
Cloning of Apoptosis Inducing Factor as therapeutic protein  
 
 
       Our EM22-intron siRNAs system has successfully shown splicing activity that has 
enabled us to obtain a functional protein from the re-joined exon, previously described as 
EGFP (Fig. 3B and Fig. 5) and also active suppression from the siRNA from the intron (Fig. 
7).  Therefore, in order to obtain a synergistic effect in treating cancer cells, the AIF gene 
was cloned, in an effort to further induce cells into apoptosis.  We designed a pair of AIF 
primers based on the PubMed (AF100927). RT-PCR was performed on cell extract from 
both B16F10 and Tc1 cell lines. We cloned a 1.93KB fragment of AIF from B16F10 cell 
line but not from the Tc1 cell line (Fig. 8A) and inserted it into the EGFP-N1 plasmid to 
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form SPL, and HHI-80 plasmids, respectively (Fig. 9). The SPL plasmid (Rep23 clone) 
contained the cloned AIF in place of EGFP in the pEGFP-N1 plasmid (Fig. 9A).  The HHI-
80 (MCS15 clone) has cloned AIF inserted upstream of the EGFP fragment (Fig. 9B). Both 
SPL and HHI-80 were sequenced and restriction digestion confirmed predicted size 
fragments (Fig. 8B). We observed the AIF transfected B16F10 cells by light microscopy 
(Fig. 10A). The SPL (e.g., AIF) transfected cells displayed obvious cell death, even in the 
absence of STS, an apoptosis inducer (Fig. 10A). MTT assays were conducted to analyze 
the cell growth inhibition activity of both SPL and HHI-80 AIF constructs and compared 
them to EM22-intron-HPV E6 siRNA (Fig. 10B). The preliminary data suggest that both 
SPL and HHI-80 can inhibit cell growth around 15-20%.  With the addition of STS, both 
SPL and HHI-80 can reach up to 25% to 30% cell growth inhibition (Fig. 10B). 
Overall, it has been shown that the novel RNA polymerase II promoter driven constructs 
(EM22-intron) successfully demonstrated the ability to correctly splice a reporter gene. As 
shown in Fig. 3B, both for forward-inserted and reverse-inserted introns are able to be 
correctly excised. It is likely that the forward-inserted intron seems to have higher splicing 
ability owning to the PPT (Poly-Pyrimidine Tract) element located much far from the 
promoter, and thus enable the RNA polymerase to go farther.  In contrast, the PPT element 
of the reversed-inserted intron is closer to the promoter and the pyrimidine-rich sequences 
of the PPT tend to act as a stop signal for the transcription reaction.  Therefore, it is not 
surprising that the forward-inserted intron has higher splicing activity. Replacing this 
reporter gene with the apoptosis inducing factor (AIF), demonstrated increased cell death as 
compared to control cells (i.e. up to 30% increase). Furthermore, it was demonstrated that 
siRNA sequences inserted into the introns were able to down-regulate gene activity up to 
11
 
40% compared to control sequences. Owning to lack of better ways to only analyze with 
those transfected cells, our results were based on the whole population of the sample cells.  
Therefore, we believed that by examining only those plasmid transfected cells, we will be 
better able to accurately measure the down-regulation ability of our EM-intron constructs.  
This system may provide interesting therapeutic options for future cancer therapeutic 
research. 
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Table1.  Primer Sequence  
 
Gene Primer sequences 
Mouse AIF 
 
 
 
 
Forward 5' - AAG GAA CCC GGG TGC GTG GAA GGA AAA GGA AGG AGC 
GGG AGC TTC CG - 3' 
Reverse 5' - TTC CTT GCG GCC GCC GCC AGG GAT GGA AAA GTG CTT 
GTG TAT TCC ACG A - 3' 
VEGF 
siRNA 
 
 
 
 
Forward 5' - AAT TAA TGA TCA CGA TCG ACG CGT GGA TCC CGC ACT 
CCA G - 3'  
Reverse 5' - TTC CTT ACT AGT AGT ACT TCG CGA AAG CTT TTG GAA 
AAA AGC ACT CCA GGG CTT CAT - 
HPV E6 
siRNA 
 
 
 
 
Forward 5' - AAT TAA TGA TCA CGA TCG ACG CGT GGA TCC CGC TTG 
CAG T - 3' 
 
Reverse 5' - TTC CTT GCG GCC GCC GCC AGG GAT GGA AAA GTG CTT 
GTG TAT TCC ACG A - 3' 
EGFR 
siRNA 
 
 
 
 
Forward 5' - AAT TAA TGA TCA CGA TCG ACG CGT GGA TCC CAG GAA 
TTC G - 3'  
Reverse 5' - TTC CTT ACT AGT AGT ACT TCG CGA AAG CTT TTG GAA 
AAA AAG GAA TTC GCT CC - 3' 
Control 
siRNA 
 
 
 
Forward 5' - AAT TAA TGA TCA CGA TCG ACG CGT GGA TCC CAC GTG 
ACA C - 3' –  
Reverse 5' - TTC CTT ACT AGT AGT ACT TCG CGA AAG CTT TTG GAA 
AAA AAC GTG ACA CGT TCG G  
EGFP-Pst I 
Mutagenesis 
 
 
 
Forward 5' - CCT GCT GGA GTT CGT GAC CGC TGC AGG GAT CAC TCT 
CGG CAT GGA C - 3' 
Reverse 5' - GTC CAT GCC GAG AGT GAT CCC TGC AGC GGT CAC GAA 
CTC CAG CAG G - 3' 
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 Biochemical and Biophysical Research Communication 
2003, p754-760  
 
 
exon2 
pol II exon1 exon2 exon x + 1 Ts Intron1 Intron x 
Insert PPT BrP DS AS 
MRS1 MRS2 
DS BrP PPT MRS1 MRS2 
exon 1+2+..x+1 + Insert BrP  PPT Intron (X) x 
Functional protein:  
Therapeutical protein 
Report gene (EGFP) 
Spliced insert 
siRNA for gene silencing Insert 
 
? 
MRS= Multiple Restriction Site 
BrP= Branch Point 
PPT=Poly-Pyrimidine Tract 
DS= Splicing Donor Site 
AS=Splicing Acceptor Site 
Ts= Termination Sequence Code 
AG  GTAAGAGT  CGATCG  SpRNAi  ACGCGT TACTAAC  TGGTACC TCTTC(T)10  
AS 
 
 
 
 
 
 Fig.1 Schematic strategy of RNA polymerase II driven siRNA and functional protein. 
A new strategy for utilizing specially designed plasmid constructs that take advantage 
of RNA splicing mechanism was proposed by Lin and collegues (Lin SL, 2003).  In 
this approach, after splicing, the RNA polymerase II leads to the production of an 
oncogene targeted siRNA from the spliced intron and a functional protein from the 
exon. 
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+Pst
-PstI
A.
 
 
pEGFP-N1       pEGFP-N1-PstI        pEGFP-N1+PstI+PstI B.  
 
Digestion with PstI  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2  Relocation of PstI site within EGFP 
The PstI site from the multiple cloning sites was removed by ScaI and XhoI and then 
religated to form a XmnI site. (pEGFP-N1-PstI).  A new PstI site within the EGFP 
was created by site-directed mutagenesis of the pEGFP-N1-PstI  to form pEGFP-
N1-PstI +PstI. Datas shows different clones of each group constructs. 
 
 
 
 
 
 
 
 
 
 
A.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DS Insert      BrP PPT AS Exon1 Exon 2
AG  GTAAGAGT TACTAA TGGTACC GATATCCTGCAG  GC
Intron
PstI
PstI 
PstI
PstI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.
Intron reverse Intron forward
EGFP EM22 (-Pst I +Pst I )
EM22- Intron ForwardEM22- Intron Reverse
 Fig.3 Insertion of artificial intron into the newly created PstI site within EGFP 
 (A) Schematic representing of Intron insertion into newly created PstI site.  (B) 
Splicing ability of both EM-PstI +PstI and EM-intron was examined by 
fluorescent microscope 
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A.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DS Insert BrP PPT ASExon1 Exon 2
AG  GTAAGAGT TACTAAC TGGTACC TCTTC(T)10 GATATCCTGCAG GC
Intron
PstI
PstI
PstI
PstI
Anti-HPV E6
Anti-EGFR 
Anti-VEGF
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Fig.4 Insertion of various siRNAs into the intron of EM system  
(a) Schematic representing of HPV E6, EGFR, VEGF siRNAs insertion into 
EM-Intron system. (B) PCR product of each siRNA fragment with the 
originally synthetic one as positive control 
Intron
89 bp
DS BrP PPT
MluI (25)
Pvu I (22) Sca I (33)
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Fig.5 Analysis of EGFP function with several EM-intron constructs 
6 siRNA, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EGFP, EM-intron, EM22-intron-control siRNA, EM22-intron-HPV E
EM22-intron-EGFR siRNA, EM22-intron-VEGF siRNA were tested their 
splicing ability by examining with fluorescent microscope 
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Fig.6   Schematic representing of RNA polymerase III vs RNA polymerase II promoter driven constructs 
II 
A commonly used RNA polymerase III promoter driven siRNA expression plasmid was purchased from 
genescript as pRNA-siRNA system to compare the siRNA expression activity with our RNA polymerase 
promoter driven siRNA expression plasmid which utilize the RNA splicing mechanism. Both system were 
successfully inserted with control siRNA, HPV E6 siRNA, EGFR siRNA , VEGF siRNA and were all 
sequence verified. 
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Fig.7 Analysis of Luciferase RNAi efficiency by luciferase assay 
uct. (B) Luciferase 
hole 
(a) Schematic representing of EM-Intron Luciferase siRNA constr
activity assay of different EM-Intron constructs. The result was normalized with the w
cell protein and further compared with the EM22 (EM-Intron) as 100 percent. 
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Fig.8  RT-PCR cloning AIF(a) RT-PCR cloning AIF of cell lysate from both B16F10 and 
TC1 cell lines with SPL, HHI-80, actin primer pairs. (B) Cloned 1.93kb AIF from B16F10 
cell line was inserted into pEGFP-N1 plasmid to form SPL and was enzyme digestion 
confirmed by predicted fragment size. The SPL construct was then sent to sequence verified. 
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Fig.9 Schematic representing of AIF cloning constructs: SPL and HHI-80  
Cloned 1.93kb AIF from B16F10 cell line was inserted into pEGFP-N1 
plasmid to form SPL (replaced EGFP) and HHI-80 (inserted ahead of 
EGFPgene). Both SPL and HHI-80 were sequence confirmed 
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Fig.10 Functional analysis of AIF  
(A) SPL transfected B16F10 cell line was observed with light microscope to exam the cell 
killing ability either with or without STS, apoptosis inducer, (B) MTT assay of cell viability 
with EGFP, SPL, HHI-80, EM-Intron-HPV E6 plasmid transfected B16F10 cell line 
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